ArticleFrontiers in oncology2026
ARHGAP44 gene: a cytoskeleton mobility-related modulator with implications in pan-cancer prognostic risk and immune regulation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rho GTPases have been a well-known family of small G proteins that regulate cellular cytoskeleton dynamics and are involved in multiple critical steps of cancer progression. However, ARHGAP44 gene, a member of GAP proteins that regulate the Rho GTPases cycling between their active GTP-bound and inactive GDP-bound states, remains poorly understood in terms of its role in cancer development. This study aims to analyze the functions of ARHGAP44 gene in a broad spectrum of human cancers, thus aiding in the better understanding of the collaborative network of cytoskeleton-related genes in cancers. Methods: The study started with the analysis of the genetic characteristics of ARHGAP44 gene, followed by its expression patterns, frequent alterations as well as survival prediction value in a broad spectrum of human cancers. Furthermore, the probable reasons for the aberrant changed expression of ARHGAP44 in cancers compared to corresponding normal control samples were investigated. Moreover, the correlation of ARHGAP44 with multiple critical clinical cancer parameters was performed in succession. Results: The basic genetic physicochemical properties of ARHGAP44 including its amino-acid composition, estimated molecular weight, and protein half-life were investigated. Then, genetic alteration analysis revealed that ARHGAP44 expression varies in human cancers, which was partly due to the modulation by DNA methylation and phosphorylation. Furthermore, ARHGAP44 gene was associated with multiple critical cancer traits including cancer stemness, cytoskeleton dynamics as well as immune infiltration in different human cancer types. Moreover, ARHGAP44 gene was also associated with the sensitivity of several chemotherapy-related drugs. Conclusions: Based on multiple analyses, some valuable strategies to guide the therapeutic orientation concerning the role of ARHGAP44 gene in human cancers were revealed, although more detailed experiments and clinical trials are obligatory to support further clinical medical applications of the gene, especially in each independent cancer type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.